Results 71 to 80 of about 3,797 (192)

AKTIVITAS ANTIVIRUS HEPATITIS C DAN SITOTOKSISITAS EKSTRAK ETANOL HERBA Ruta angustifolia L KOMBINASI DENGAN HERBA Phyllanthus niruri L, RIMPANG Curcuma domestica DAN OBAT SIMEPREVIR SECARA IN VITRO [PDF]

, 2022
Hepatitis C merupakan suatu penyakit yang berpengaruh pada kesehatan masyarakat di dunia. Indonesia juga termasuk negara yang terdampak penyakit hepatitis C. Hingga saat ini, belum ditemukan vaksin untuk virus hepatitis C (Depkes RI, 2013).
VIKA DIAJENG RIZKI MAULIDA
core  

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection [PDF]

, 2016
The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial.
Morelli,, Watts,, Szabo,, Williams,, Morelli, Giuseppe, Fenkel,, Kuo,, Galati,, Gordon,, Kwo,, Spivey,, Afdhal,, Reddy,, Jacobson, Ira M., Mailliard,, Shiffman,, Alam,, Harlan,, Brown, Robert S., Hassan,, Lim,, Sulkowski,, Terrault,, Darling,, Pearlman,, Hawkins,, Levitsky,, Lok,, Zeuzem,, Elbeshbeshy,, Schiff,, Ben-Ari,, Muir,, Sherman,, Vargas,, Lim, Joseph K., Frazier, Lynn M., Fried,, Trautwein,, Ramani,, Everson,, Jacobson,, Bredfeldt,, Stewart, Thomas G., Chung,, Brown,, Reddy, K. Rajender, Di Bisceglie, Adrian M., Feld, Jordan J., Darling, Jama M., Nelson, David R., Dickson,, Hinestrosa,, Kerr,, Manns,, Pockros,, Nelson,, O'Leary,, Kuo, Alexander, Di Bisceglie,, Sterling,, Reau,, Smith,, Sulkowski, Mark S., Feld,, Fried, Michael W.   +65 more
core   +2 more sources

Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia

Case Reports in Hematology, 2016
Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin
Nikolaos Papadopoulos, Melanie Deutsch, Athanasios Georgalas, Helias Poulakidas, Lazaros Karnesis   +4 more
doaj   +1 more source

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

Case Reports in Gastroenterology, 2015
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +11 more
doaj   +1 more source

Alphavirus nsP2: A Multifunctional Regulator of Viral Replication and Promising Target for Anti‐Alphavirus Therapies

Reviews in Medical Virology, Volume 35, Issue 2, March 2025.
ABSTRACT Alphaviruses are re‐emerging vector‐born pathogens that cause arthralgia or encephalitic diseases on a global scale. While a vaccine against chikungunya virus was recently approved, no vaccines currently exist for other alphaviruses, nor are there antiviral drugs for the treatment of alphavirus infections. Alphaviruses have positive‐strand RNA
Sainan Wang, Suresh Mahalingam, Andres Merits   +2 more
wiley   +1 more source

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Advances in Virology, 2020
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities.
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany, Sherief Abd-Elsalam   +9 more
doaj   +1 more source

Additional file 2: of Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

, 2017
Figure S1. Mean (SD) plasma concentration versus time profile for: (a) simeprevir; (b) TMC647055; and (c) ritonavir in Panels 1–4; and for (d) JNJ-56914845 in Panel 4. RBV ribavirin, RTV ritonavir, SD standard deviation, SMV simeprevir.
Christophe Moreno (798309), Donghan Luo (3741448), Bert Jacquemyn (3741460), RenĂŠ Verloes (3741472), Frederik Nevens (243993), Hans Orlent (3710239), Keikawus ArastĂŠh (3741475), Leen Vijgen (1833772), Eva Hoeben (3741451), Pieter Van Remoortere (1833745), Peter Buggisch (587274), Stefan Bourgeois (3710266), Hans Van Vlierberghe (707104), JĂśrn Schattenberg (3528266), Thomas Kakuda (3741442), Yves Horsmans (3741445), Sven Francque (602244), An Vandebosch (3741457)   +17 more
core   +1 more source

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice

Журнал инфектологии, 2016
The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical ...
N. P. Blokhina, E. A. Nurmuhametova, M. G. Rusanova, I. V. Gagarina, E. S. Mar’jamova, N. A. Kuznetsova, T. V. Mar’janovskaja, T. V. Lopatina, O. V. Kuzina, I. N. Alekseeva, E. N. Shurenkova, A. V. Devjatkin, Yu. N. Linkova, M. A. Morozova   +13 more
doaj  

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

, 2016
Since 2014 several direct-acting antivirals (DAAs) have been made available, allowing interferon-free antiviral treatments with high sustained virological response rates. Side effects are, however, a real challenge during treatment.
Festa, Elena, Casari, Salvatore, Castelli, Francesco, Izzo, Ilaria, Zanotti, Paola, Biasi, Luciano, Villanacci, Vincenzo, Chirico, Claudia, Salemme, Marianna   +8 more
core   +1 more source

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications [PDF]

, 2018
Aims: Direct-acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug–drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood.
Ronald Kalmeijer, Höner zu Siederdissen, C, Schlag, M, David Back, Jessner, W, Cornberg, M, Lonjon-Domanec, I, Maria Beumont-Mauviel, Bicer, C, Back, D, Markus Cornberg, Beumont-Mauviel, M, Wolfgang Jessner, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Fiona Marra, Christoph Höner zu Siederdissen, Marra, F, Saye Khoo, Khoo, S, Ouwerkerk-Mahadevan, S, Isabelle Lonjon-Domanec, Michael Schlag, Kalmeijer, R   +23 more
core   +1 more source